Positive Results of BioGlue(R) in Treating Alveolar Air Leaks Presented at International Medical Conference
ATLANTA, Sept 28, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials and biosurgical device company, announced today the positive results of a study on the use of BioGlue(R) Surgical Adhesive to treat alveolar air leaks after surgical procedures were presented this week at the European Association for Cardio-Thoracic Surgery in Barcelona, Spain. Patients in the study who were treated with BioGlue had a shorter median duration of air leaks, chest tube drainage, and hospital stay. No major complications were encountered from using BioGlue. There were 52 patients in the study.
This study was conducted by Professor Peter Goldstraw at the Royal Brompton Hospital in London. It was a prospective, randomized, single-blind, controlled trial conducted in which patients were stratified according to severity of post-thoracotomy air leak that could not be controlled by conventional surgical techniques. The aim of this study was to determine the efficacy of BioGlue in eliminating air leaks after lung resection surgery.
About CryoLife
Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiovascular, vascular, and orthopaedic surgeries throughout the United States and Canada. The Company's BioGlue(R) Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels and is CE marked in the European Community and approved in Canada for use in soft tissue repair and approved in Australia for use in vascular and pulmonary sealing and repair.
Statements made in this press release that look forward in time or that express management's beliefs, expectations or hopes are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These future events may not occur as and when expected, if at all, and, together with the Company's business, are subject to various risks and uncertainties. These risks and uncertainties include that future studies will not prove as promising with regard to the performance of BioGlue(R) in treatment of alveolar air leaks after surgical procedures, that the Company's 2005 revenues and expenses may not meet its expectations, the possibility that the FDA or other regulatory authorities could impose additional restrictions on the Company's operations, require a recall, or prevent the Company from processing and distributing tissues or manufacturing and distributing other products, that the Company may not have sufficient capital availability to fund its business, that pending litigation cannot be settled on terms acceptable to the Company, that the Company may not have sufficient resources to pay punitive damages (which are not covered by insurance) or other liabilities in excess of available insurance, the possibility of severe decreases in the Company's revenues and working capital, that to the extent the Company does not have sufficient resources to pay the claims against it, it may be forced to cease operations or seek protection under applicable bankruptcy laws, changes in laws and regulations applicable to CryoLife and other risk factors detailed in CryoLife's Securities and Exchange Commission filings, including CryoLife's Form 10-K filing for the year ended December 31, 2004, its registration statement on Form S-3 (Reg. No. 333-121406), and the Company's other SEC filings. The Company does not undertake to update its forward-looking statements.
For additional information about the Company, visit CryoLife's Web site: http://www.cryolife.com
Contact: Joseph T. Schepers
Vice President, Corporate Communications
(770) 419-3355
SOURCE CryoLife, Inc.